IL218034A0 - Oxazine derivatives and their use in the treatment of neurological disorders - Google Patents

Oxazine derivatives and their use in the treatment of neurological disorders

Info

Publication number
IL218034A0
IL218034A0 IL218034A IL21803412A IL218034A0 IL 218034 A0 IL218034 A0 IL 218034A0 IL 218034 A IL218034 A IL 218034A IL 21803412 A IL21803412 A IL 21803412A IL 218034 A0 IL218034 A0 IL 218034A0
Authority
IL
Israel
Prior art keywords
treatment
neurological disorders
oxazine derivatives
oxazine
derivatives
Prior art date
Application number
IL218034A
Other languages
English (en)
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45468934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL218034(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2010/060718 external-priority patent/WO2011009943A1/en
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of IL218034A0 publication Critical patent/IL218034A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
IL218034A 2010-07-13 2012-02-09 Oxazine derivatives and their use in the treatment of neurological disorders IL218034A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36370210P 2010-07-13 2010-07-13
PCT/EP2010/060718 WO2011009943A1 (en) 2009-07-24 2010-07-23 Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders
US201161432058P 2011-01-12 2011-01-12
US201161435088P 2011-01-21 2011-01-21
PCT/CN2011/077119 WO2012006953A1 (en) 2010-07-13 2011-07-13 Oxazine derivatives and their use in the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
IL218034A0 true IL218034A0 (en) 2012-04-30

Family

ID=45468934

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218034A IL218034A0 (en) 2010-07-13 2012-02-09 Oxazine derivatives and their use in the treatment of neurological disorders

Country Status (31)

Country Link
US (2) US20120302558A1 (instruction)
EP (1) EP2483255B1 (instruction)
JP (1) JP5128019B1 (instruction)
KR (2) KR101265451B1 (instruction)
CN (1) CN102666507B (instruction)
AU (1) AU2011278825B2 (instruction)
BR (1) BR112012004154A2 (instruction)
CA (1) CA2771928C (instruction)
CO (1) CO6501189A2 (instruction)
DK (1) DK2483255T3 (instruction)
EA (1) EA020008B1 (instruction)
EC (1) ECSP12011692A (instruction)
ES (1) ES2442905T3 (instruction)
HR (1) HRP20140011T1 (instruction)
IL (1) IL218034A0 (instruction)
IN (1) IN2012DN01269A (instruction)
MA (1) MA33509B1 (instruction)
MX (1) MX2012002439A (instruction)
MY (1) MY150939A (instruction)
NZ (1) NZ598137A (instruction)
PE (1) PE20121617A1 (instruction)
PH (1) PH12012500361A1 (instruction)
PL (1) PL2483255T3 (instruction)
PT (1) PT2483255E (instruction)
RS (1) RS53096B (instruction)
SG (1) SG178311A1 (instruction)
SI (1) SI2483255T1 (instruction)
TN (1) TN2012000067A1 (instruction)
TW (1) TWI421250B (instruction)
WO (1) WO2012006953A1 (instruction)
ZA (1) ZA201200880B (instruction)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612854B1 (en) 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
WO2008133274A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. 環式基で置換されたアミノジヒドロチアジン誘導体
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MY153621A (en) 2008-06-13 2015-02-27 Shionogi & Co Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
EP4487799A3 (en) 2008-09-26 2025-03-19 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
PT2411393E (pt) 2009-03-23 2014-02-21 Glenmark Pharmaceuticals Sa Derivados de pirimidina-diona fundidos como moduladores de trpa1
JP2012521406A (ja) 2009-03-23 2012-09-13 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としてのフロピリミジンジオン誘導体
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
ES2590038T5 (es) 2009-12-11 2021-10-19 Shionogi & Co Derivado de oxazina
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
US8524897B2 (en) * 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
CN103429589A (zh) * 2011-01-12 2013-12-04 诺瓦提斯公司 噁嗪衍生物及其在治疗神经障碍中的用途
CN103596569A (zh) * 2011-01-13 2014-02-19 诺瓦提斯公司 用于治疗代谢障碍的bace-2抑制剂
ME02409B (me) 2011-01-13 2016-09-20 Novartis Ag Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja
US8815841B2 (en) 2011-02-18 2014-08-26 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9499502B2 (en) 2011-04-13 2016-11-22 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
MX2014002113A (es) 2011-08-22 2014-04-25 Merck Sharp & Dohme Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso.
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
US9556135B2 (en) 2012-10-12 2017-01-31 Amgen, Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
AU2013363151A1 (en) 2012-12-20 2015-06-04 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
US9489376B2 (en) * 2013-01-02 2016-11-08 International Business Machines Corporation Identifying confidential data in a data item by comparing the data item to similar data items from alternative sources
CN105061305A (zh) * 2015-08-31 2015-11-18 河南师范大学 一步合成3-甲基-2-吡啶甲酸甲酯的方法
CN107723290A (zh) * 2017-08-14 2018-02-23 蔡祥胜 一种重组人卵细胞透明带zp3蛋白及其制备方法
CN112250580A (zh) * 2020-10-28 2021-01-22 上海昂卓新材料科技有限公司 一种2-硝基-2-取代苯基丙烷-1,3-二醇的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
NZ548128A (en) 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
TW200624426A (en) * 2004-09-21 2006-07-16 Lilly Co Eli BACE inhibitors
EP2612854B1 (en) * 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
EP2151435A4 (en) * 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2008133274A1 (ja) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. 環式基で置換されたアミノジヒドロチアジン誘導体
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
PE20091438A1 (es) 2008-01-18 2009-09-26 Eisai Randd Man Co Ltd Derivados fusionados de aminodihidrotiazina
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
US8188079B2 (en) * 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines

Also Published As

Publication number Publication date
RS53096B (en) 2014-06-30
KR101265451B1 (ko) 2013-05-22
JP2013508314A (ja) 2013-03-07
MX2012002439A (es) 2012-04-10
MY150939A (en) 2014-03-14
HK1168091A1 (en) 2012-12-21
HRP20140011T1 (hr) 2014-01-31
EA020008B1 (ru) 2014-07-30
US20120172359A1 (en) 2012-07-05
TN2012000067A1 (en) 2013-09-19
CN102666507A (zh) 2012-09-12
CO6501189A2 (es) 2012-08-15
IN2012DN01269A (instruction) 2015-05-15
PE20121617A1 (es) 2012-12-14
SI2483255T1 (sl) 2014-02-28
US20120302558A1 (en) 2012-11-29
EA201200176A1 (ru) 2012-09-28
EP2483255B1 (en) 2013-10-16
EP2483255A1 (en) 2012-08-08
CA2771928C (en) 2013-08-06
MA33509B1 (fr) 2012-08-01
PL2483255T3 (pl) 2014-03-31
CA2771928A1 (en) 2012-01-19
KR20130016195A (ko) 2013-02-14
TWI421250B (zh) 2014-01-01
PH12012500361A1 (en) 2012-01-19
KR101391041B1 (ko) 2014-05-07
DK2483255T3 (da) 2014-01-20
AU2011278825B2 (en) 2012-09-20
AU2011278825A1 (en) 2012-03-01
KR20120068839A (ko) 2012-06-27
BR112012004154A2 (pt) 2017-05-30
ECSP12011692A (es) 2012-03-30
WO2012006953A1 (en) 2012-01-19
ES2442905T3 (es) 2014-02-14
NZ598137A (en) 2014-06-27
TW201211038A (en) 2012-03-16
ZA201200880B (en) 2012-08-29
PT2483255E (pt) 2014-01-22
CN102666507B (zh) 2014-09-17
SG178311A1 (en) 2012-03-29
EP2483255A4 (en) 2013-01-09
JP5128019B1 (ja) 2013-01-23

Similar Documents

Publication Publication Date Title
IL218034A0 (en) Oxazine derivatives and their use in the treatment of neurological disorders
AP3807A (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
IL220268A0 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
ZA201200155B (en) Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders
IL223241A0 (en) Cysteamine derivatives and their use in the treatment of nash
AP2014007601A0 (en) Novel purine derivatives and their use in the treatment of disease
IL221874A (en) History of pyrimidine and their use in the treatment of respiratory diseases such as copd
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
RS56595B1 (sr) Derivati estrogena za upotrebu u lečenju neuroloških poremećaja
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
GB0904044D0 (en) The treatment of inflammatory disorders and pain
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
GB201222455D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
IL233875A (en) Preparation and use for the treatment of anal fissures
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
PT2670769T (pt) R2r1/2 em diagnóstico e terapêutica
IL231609A (en) Benzene propanamide and benzene propanamide transforms n for use in the prevention and treatment of emotional disorders
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
IL235066A0 (en) Sorcs1 for use in the treatment of obesity and overweight
EP2934699A4 (en) PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN
AU2010901520A0 (en) Substituted thienobenzodiazepines and their use in the treatment of CNS disorders
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina
AU2012905072A0 (en) The use of bucillamine in the treatment of gout
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer